Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
23 Most Amusing Messages At any point Sent Among Kids and Their Folks - 2Germany to create restitution council to return colonia-era acquired cultural artefacts
- 3Solid Propensities: Little Changes for a Superior Life
- 4Select Your Definitive Pizza Decision
- 5'Always put others first': IDF reservist who died while on leave saves four with organ transplants
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
- SUVs Known for Their Looks As opposed to Their Capacity
- Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals
- 4 injured in shooting at North Carolina tree lighting ceremony
- Kelsey Grammer on having a new baby at 70: 'You're just more available now'
- Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- When darkness shines: How dark stars could illuminate the early universe
- No more attempts to free whale stranded off Germany, officials say
- Orbán orders stop to gas deliveries to Ukraine via Hungary from July
